JP2004510439A5 - - Google Patents

Download PDF

Info

Publication number
JP2004510439A5
JP2004510439A5 JP2002532652A JP2002532652A JP2004510439A5 JP 2004510439 A5 JP2004510439 A5 JP 2004510439A5 JP 2002532652 A JP2002532652 A JP 2002532652A JP 2002532652 A JP2002532652 A JP 2002532652A JP 2004510439 A5 JP2004510439 A5 JP 2004510439A5
Authority
JP
Japan
Prior art keywords
present
addressin
antibody
fragment
construed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002532652A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004510439A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2001/000632 external-priority patent/WO2002029083A2/en
Publication of JP2004510439A publication Critical patent/JP2004510439A/ja
Publication of JP2004510439A5 publication Critical patent/JP2004510439A5/ja
Pending legal-status Critical Current

Links

JP2002532652A 2000-10-02 2001-10-02 哺乳動物細胞における組換えタンパク質の工業的規模の無血清製造法 Pending JP2004510439A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DKPA200001456 2000-10-02
US23894400P 2000-10-10 2000-10-10
DKPA200100262 2001-02-16
US27158101P 2001-02-26 2001-02-26
DKPA200100430 2001-03-14
US27632201P 2001-03-16 2001-03-16
DKPA200100751 2001-05-14
PCT/DK2001/000632 WO2002029083A2 (en) 2000-10-02 2001-10-02 Industrial-scale serum-free production of recombinant proteins in mammalian cells

Publications (2)

Publication Number Publication Date
JP2004510439A JP2004510439A (ja) 2004-04-08
JP2004510439A5 true JP2004510439A5 (enExample) 2005-03-03

Family

ID=27439823

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2002532615A Expired - Fee Related JP4361730B2 (ja) 2000-10-02 2001-10-02 ビタミンｋ−依存性タンパク質の生成方法
JP2002532652A Pending JP2004510439A (ja) 2000-10-02 2001-10-02 哺乳動物細胞における組換えタンパク質の工業的規模の無血清製造法
JP2002532653A Pending JP2004512835A (ja) 2000-10-02 2001-10-02 哺乳動物細胞における組換えｆｖｉｉの工業的規模の無血清製造法
JP2002532595A Expired - Fee Related JP4477299B2 (ja) 2000-10-02 2001-10-02 因子ｖｉｉグリコ型

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002532615A Expired - Fee Related JP4361730B2 (ja) 2000-10-02 2001-10-02 ビタミンｋ−依存性タンパク質の生成方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2002532653A Pending JP2004512835A (ja) 2000-10-02 2001-10-02 哺乳動物細胞における組換えｆｖｉｉの工業的規模の無血清製造法
JP2002532595A Expired - Fee Related JP4477299B2 (ja) 2000-10-02 2001-10-02 因子ｖｉｉグリコ型

Country Status (18)

Country Link
US (6) US8202973B2 (enExample)
EP (6) EP1325127B1 (enExample)
JP (4) JP4361730B2 (enExample)
KR (2) KR100880624B1 (enExample)
CN (3) CN1481438A (enExample)
AT (2) ATE425254T1 (enExample)
AU (5) AU2001291652B2 (enExample)
BR (2) BR0114374A (enExample)
CA (2) CA2422214A1 (enExample)
CZ (1) CZ2003718A3 (enExample)
DE (2) DE60141908D1 (enExample)
ES (2) ES2323761T3 (enExample)
HU (2) HUP0301245A3 (enExample)
IL (2) IL154880A0 (enExample)
MX (1) MXPA03002853A (enExample)
NO (1) NO20031471L (enExample)
PL (2) PL361058A1 (enExample)
WO (4) WO2002029084A2 (enExample)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7786070B2 (en) 1997-09-10 2010-08-31 Novo Nordisk Healthcare A/G Subcutaneous administration of coagulation factor VII
US20050032690A1 (en) * 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
BRPI9910332B8 (pt) 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
EP1982732A3 (en) 2000-02-11 2011-06-08 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
HUP0402158A2 (hu) 2001-10-02 2005-01-28 Novo Nordisk Health Care Ag Rekombináns fehérjék előállítási eljárása eukarióta sejtekben
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
RU2357751C2 (ru) 2001-12-21 2009-06-10 Ново Нордиск Хелт Кэр Аг Жидкая композиция полипептидов фактора vii
US7700733B2 (en) * 2002-04-30 2010-04-20 Bayer Healthcare Llc Factor VII or VIIa polypeptide variants
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
BR0311978A (pt) * 2002-06-21 2005-03-22 Novo Nordisk Healthcare Ag Preparação, método para preparar a mesma, formulação farmacêutica, métodos para tratar de uma sìndrome responsiva ao fator vii, para prevenir hemorragias indesejáveis, para prevenir coagulação sanguìnea indesejável e para prevenir as reações mediadas pelo fator tecidual, e, uso de uma preparação
BRPI0311959B8 (pt) 2002-06-21 2021-05-25 Novo Nordisk Healthcare Ag composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii
EP1549677B1 (en) * 2002-09-30 2011-04-13 Bayer HealthCare LLC FVII OR FVIIa VARIANTS HAVING INCREASED CLOTTING ACTIVITY
AU2004222625A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides
AU2004221758B2 (en) * 2003-03-18 2010-07-22 Novo Nordisk Health Care Ag Method for the production of GLA-residue containing serine proteases
DK2085470T3 (da) 2003-03-20 2012-08-06 Bayer Healthcare Llc FVII- eller FVIIa-varianter
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
NZ542586A (en) 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
RU2364609C2 (ru) * 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Стабилизация белка в растворе
DK1644504T3 (da) * 2003-06-19 2010-05-25 Bayer Healthcare Llc Faktor VII- eller -VIIA-Gla-domænevarianter
WO2004112828A1 (en) * 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
US7687478B2 (en) * 2003-06-30 2010-03-30 Otsuka Chemical Co., Ltd. Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same
ATE446768T1 (de) * 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
AU2004264282B2 (en) 2003-08-14 2010-10-14 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of Factor VII polypeptides
EP2392655A3 (en) 2003-09-09 2012-02-29 Novo Nordisk Health Care AG Coagulation factor VII polypeptides
PT2380985E (pt) 2003-09-23 2014-03-26 Univ North Carolina Células que expressam a vitamina k epóxido reductase e sua utilização
JP4740138B2 (ja) 2003-10-10 2011-08-03 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 真核生物細胞におけるポリペプチドの大規模生産方法及びそれに適した培養容器
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
DK2189523T3 (da) 2003-10-14 2012-03-12 Baxter Int VKORC1 (vitamin K-epoxid-tilbageføringspolypeptid), et terapeutisk mål for coumarin og dets derivater
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
CN106916802B (zh) 2003-12-01 2022-03-25 诺和诺德医疗保健公司 液体因子vii组合物的病毒过滤
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
KR20150138427A (ko) * 2003-12-19 2015-12-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
WO2005068620A1 (en) * 2004-01-07 2005-07-28 Novo Nordisk Health Care Ag Method for the production of recombinant proteins
KR20070008645A (ko) 2004-05-04 2007-01-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 폴리펩티드의 ｏ-연결된 단백당형 및 그들의 제조 방법
BRPI0514396A2 (pt) * 2004-08-17 2009-05-12 Csl Behring Gmbh polipeptìdeos dependentes de vitamina k modificada
JP2008514216A (ja) * 2004-09-29 2008-05-08 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｄｅｓｇｌａ−ｖｉｉ因子ポリペプチド構造の除去による、ｖｉｉ因子ポリペプチドの原体の精製
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
EP1831363A1 (en) * 2004-12-21 2007-09-12 Novo Nordisk Health Care AG Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems
JP2008525381A (ja) * 2004-12-23 2008-07-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 関心のあるビタミンｋ依存性タンパク質を含んでなる組成物中におけるタンパク質混入物の量の減少
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
ES2380485T3 (es) 2005-02-11 2012-05-14 Novo Nordisk Health Care Ag Producción de un polipéptido en un líquido de cultivo sin suero con hidrolizado de proteínas vegetales
PT1853700E (pt) 2005-02-28 2013-01-14 Baxter Int Co-expressão recombinante da subunidade 1 da vitamina k epóxido redutase para melhorar a expressão de proteína dependente de vitamina
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
WO2006110083A1 (en) 2005-04-13 2006-10-19 Astrazeneca Ab A host cell comprising a vector for production of proteins requiring gamma-carboxylation
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
PL1969127T5 (pl) * 2005-12-21 2018-02-28 Cnj Holdings, Inc Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2004214B1 (en) 2006-03-16 2012-11-07 STELLARIS PHARMACEUTICALS Aps Local treatment with factor vii
DE602007007923D1 (de) * 2006-04-11 2010-09-02 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
FR2901707B1 (fr) * 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
WO2008009635A2 (en) * 2006-07-17 2008-01-24 Novo Nordisk Health Care Ag Factor viia analogues with increased activity for treating thrombocytopenia
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
WO2008056816A1 (fr) * 2006-11-07 2008-05-15 Kyoto University Support de suspension pour une molécule d'acide nucléique linéaire, procédé d'extension d'une molécule d'acide nucléique linéaire et spécimen de molécule d'acide nucléique linéaire
AU2007333049B2 (en) * 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
CA2673459C (en) 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
WO2008081024A1 (en) * 2007-01-03 2008-07-10 Novo Nordisk Health Care Ag Subcutaneous administration of coagulation factor viia-related popypeptdes
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
EP2481797A1 (en) * 2007-04-13 2012-08-01 Catalyst Biosciences, Inc. Modified factor VII polypeptides and uses thereof
AU2014202989B2 (en) * 2007-04-26 2016-07-07 Aptevo Biotherapeutics Llc Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
AU2016238889B2 (en) * 2007-04-26 2019-06-27 Aptevo Biotherapeutics Llc Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
CA2683423C (en) * 2007-04-26 2020-10-27 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
EP2014299A1 (en) * 2007-07-11 2009-01-14 Novo Nordisk A/S Subcutaneous administration of coagulation factor VII
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
WO2009086400A2 (en) 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations
DK2257311T3 (da) 2008-02-27 2014-06-30 Novo Nordisk As Konjugerede Faktor VIII-Molekyler
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
DK2349314T3 (da) 2008-10-21 2013-05-27 Baxter Int Lyofiliserede præparater af rekombinant VWF
HUE026210T2 (en) * 2008-11-12 2016-05-30 Baxalta Inc Procedure for serum-free, insulin-free VII. factor
JP5027106B2 (ja) * 2008-12-25 2012-09-19 一般財団法人阪大微生物病研究会 日本脳炎ウイルス抗原
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
WO2011012850A2 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
US8637640B2 (en) 2009-07-27 2014-01-28 Baxter International Inc. Blood coagulation protein conjugates
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
EP2494040B1 (en) * 2009-10-30 2018-08-29 Aptevo BioTherapeutics LLC Method of producing recombinant vitamin k dependent proteins
WO2011069056A2 (en) * 2009-12-04 2011-06-09 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
FR2954349A1 (fr) 2009-12-22 2011-06-24 Agronomique Inst Nat Rech Sulfatase modifiant selectivement les glycosaminoglycanes
WO2012075138A1 (en) * 2010-11-30 2012-06-07 Progenetics Llc Method of producing biologically active vitamin k dependent proteins in transgenic animals
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
PL2654794T3 (pl) 2010-12-22 2020-07-27 Baxalta GmbH Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2906236A1 (en) 2012-10-10 2015-08-19 Novo Nordisk Health Care AG Liquid pharmaceutical composition of factor vii polypeptide
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
FR3006591B1 (fr) 2013-06-11 2016-05-06 Lab Francais Du Fractionnement Composition de facteur vii presentant un point isoelectrique substantiellement homogene
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015158696A1 (en) * 2014-04-16 2015-10-22 Cmc Biologics A/S A high cell density fill and draw fermentation process
SG10202113019XA (en) 2014-06-04 2021-12-30 Amgen Inc Methods for harvesting mammalian cell cultures
US9714302B2 (en) 2014-10-10 2017-07-25 W. R. Grace & Co.—Conn. Process for preparing spherical polymerization catalyst components for use in olefin polymerizations
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
WO2017025566A1 (en) * 2015-08-10 2017-02-16 Glycotope Gmbh Improved recombinant factor vii
ES2803773T3 (es) * 2015-12-02 2021-01-29 CSL Behring Lengnau AG Medios mejorados para la expresión de proteínas recombinantes dependientes de vitamina k
EP3488858A1 (en) 2017-11-27 2019-05-29 Laboratoire Français du Fractionnement et des Biotechnologies A von willebrand factor composition for use in treating a pathology mediated by angiogenesis
WO2021030787A1 (en) 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
CN117434281B (zh) * 2023-10-18 2026-01-06 上海太阳生物技术有限公司 组合物、检测试剂、检测试剂盒以及在制备检测凝血因子x活性中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189534A (en) * 1976-11-11 1980-02-19 Massachusetts Institute Of Technology Cell culture microcarriers
US4357422A (en) * 1980-08-14 1982-11-02 Massachusetts Institute Of Technology Method of enhancing interferon production
US4335215A (en) * 1980-08-27 1982-06-15 Monsanto Company Method of growing anchorage-dependent cells
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4664912A (en) * 1984-10-01 1987-05-12 Wiktor Tadeusz J Process for the large scale production of rabies vaccine
US4978616A (en) * 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
SE464816B (sv) * 1985-10-15 1991-06-17 Nilsson Kjell Makroporoesa partiklar, foerfarande foer dess framstaellning och dess anvaendning
US4783940A (en) * 1985-12-28 1988-11-15 Shimizu Construction Co., Ltd. Concrete filled steel tube column and method of constructing same
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5576194A (en) * 1986-07-11 1996-11-19 Bayer Corporation Recombinant protein production
JPH01502080A (ja) * 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター 組み換えビタミンｋ依存性蛋白質のガンマカルボキシル化の増強
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
EP0540650A1 (en) 1990-07-23 1993-05-12 Zymogenetics, Inc. Gamma-carboxylase and methods of use
EP0785273A1 (en) * 1990-11-26 1997-07-23 Genetics Institute, Inc. Paired basic amino acid converting enzyme and DNA sequence encoding it
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
WO1992015686A1 (en) * 1991-02-28 1992-09-17 Zymogenetics, Inc. Modified factor vii
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5268275A (en) * 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
IL104385A (en) * 1992-01-17 1995-12-31 Applied Research Systems Method and device for growing biomass particles
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
WO1993022448A1 (en) * 1992-05-01 1993-11-11 Teijin Limited Fed batch culture method for protein secreting cells
DE4221863C2 (de) 1992-07-03 1997-04-17 Stockhausen Chem Fab Gmbh Copolymere der Allyliminodiessigsäure mit ungesättigten Carbonsäuren und deren Verwendung als Komplexbildner, Peroxidstabilisatoren, Builder in Wasch- und Reinigungsmitteln und Dispergatoren
US5510328A (en) * 1994-04-28 1996-04-23 La Jolla Cancer Research Foundation Compositions that inhibit wound contraction and methods of using same
WO1998004680A1 (en) * 1996-07-26 1998-02-05 University Of Manitoba Serum-free medium for growth of anchorage-dependant mammalian cells
PT973544E (pt) * 1997-04-08 2001-12-28 Baxter Ag Preparacao de complexo de protrombina imunotolerante
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
ATE408020T1 (de) * 1998-11-06 2008-09-15 Novo Nordisk Healthcare Ag Verfahren zur herstellung von faktor vii
AU3629800A (en) * 1999-03-16 2000-10-04 Children's Hospital Of Philadelphia, The Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
ATE330003T1 (de) * 1999-08-05 2006-07-15 Baxter Ag Rekombinanter stabiler zellklon, seine herstellung und verwendung
UA74557C2 (en) * 1999-09-03 2006-01-16 Applied Research Systems A method for producing a heterologous secreted protein from chinese hamster ovaries cells grown on microcarriers
AU7048901A (en) * 2000-04-26 2001-11-07 Aventis Pharma Gmbh Edg8 receptor, its preparation and use

Similar Documents

Publication Publication Date Title
ES2523837T3 (es) Agentes de unión específica al factor de crecimiento de hepatocitos
ATE505542T1 (de) Tumorassoziierte antigenderivate der mage-familie,zur herstellung von fusionsproteinen mit t-helper epitope und zusammensetzungen zur impfung
IL161016A (en) Polypeptides capable of ang-2 binding
SI1957539T1 (sl) Humana monoklonska protitelesa proti protein tirozin kinazi 7 (PTK7) in njihova uporaba
JP2002533123A5 (enExample)
ATE403439T1 (de) Lyophilisierte zubereitung enthaltend antikörper gegen den egf-rezeptor
EP1554311A4 (en) HUMANIZED ANTIBODIES RECOGNIZING BETA AMYLOID PEPTIDE
DE69936391D1 (de) Enterales nahrungsmittel, welches hydrolysiertes sojaprotein und teilweise hydrolysiertes caseinat enthält
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
NO20043564L (no) Follistatindomene som inneholder proteiner
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
WO2001049728A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
WO1999003987A3 (fr) Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
NO20042173L (no) Fremgangsmate for fremstilling av rekombinant polypeptid
ITRM990803A0 (it) Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
ATE537186T1 (de) P53-bindendes polypeptid
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
IL145689A0 (en) Methods
HUP0103152A3 (en) Monoclonal antibodies directed against the g3bp protein, and uses
AU2002365269A8 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
IS8308A (is) Amínósýrur með sækni fyrir a2o prótíninu
WO2002055560A3 (en) Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c
NO20022147L (no) Mimetiske peptider for epitope av apolipoprotein B-100, konkatamer og modifiserte peptider derav, og vaksinesammensetningsom omfatter det samme
IS6143A (is) Peptíð úr TT veiruröð og einsérhæfð mótefni, sem bindast TT veirunni